Lightspeed is a large Silicon Valley venture firm best known for software, whose health practice backs cancer diagnostics, AI drug discovery and digital oncology companies.
Lightspeed Venture Partners is a multi-stage venture firm founded in 2000 and headquartered in Menlo Park, with a health and biotech practice investing in techbio, diagnostics, digital health and therapeutics platforms. In oncology it has backed companies that sit at the boundary of software and biology, such as AI-driven discovery and data companies, as well as care delivery. Portfolio links in OnCo are derived from the startup records that name it.
| Company | Stage | Type | Cancers | Latest round |
|---|---|---|---|---|
| Alpha-9 Oncology Vancouver, CA | Growth stage | radiopharma | Melanoma | Series C 2024, $175M |
| Enlaza Therapeutics La Jolla, CA, US | Startup | biotech | Series A 2024, $100M | |
| Pheon Therapeutics London, GB | Startup | biotech | Series B 2024, $120M | |
| Triana Biomedicines Lexington, MA, US | Startup | biotech | Non-small-cell lung cancerHR-positive / HER2-negative breast cancer | Series B 2025, $120M |
Shares Enlaza Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Pheon Therapeutics, Triana Biomedicines and the tag vc.
Shares Enlaza Therapeutics, Alpha-9 Oncology and the tag vc.
Shares Pheon Therapeutics and the tag vc.
Shares Pheon Therapeutics and the tag vc.
Shares Alpha-9 Oncology and the tag vc.
Shares Pheon Therapeutics and the tag vc.
Shares Alpha-9 Oncology, Triana Biomedicines and the tag vc.